Immunotherapy for Elderly Patients with Advanced Non-Small Cell Lung Cancer: Challenges and Perspectives
International Journal of Molecular Sciences · 27.02.2025 · 26 (5) · 2120
DOI: 10.3390/ijms26052120 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 27.02.2025. Verfasst von Anass Baladi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Mohammed VI University Hospital, Marrakech 40000, Morocco. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Immunotherapy, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 107 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Lung cancer, a leading cause of cancer-related mortality, disproportionately affects the elderly, who face unique challenges due to comorbidities and reduced organ function. Immune checkpoint inhibitors (ICIs) offer a more tolerable alternative to chemotherapy, but their efficacy and safety in elderly non-small cell lung cancer (NSCLC) patients remain underexplored due to limited representation in clinical trials. A narrative literature review was conducted using PubMed, Embase, and the Cochrane Library to evaluate studies on elderly NSCLC patients (≥65 years) treated with ICIs. Key outcomes assessed included overall survival, progression-free survival, response rates, treatment-related adverse events, and the influence of immunosenescence on treatment efficacy. The review highlighted evidence supporting the efficacy and safety of ICIs in elderly NSCLC patients, particularly those with good performance status. Age-related immunosenescence may affect outcomes, emphasizing the need for individualized treatment. Limited data suggest ICIs alone may be preferable to chemo-immunotherapy for patients over 75 years. However, the exclusion of elderly patients from clinical trials and methodological limitations reduces the generalizability of these findings. ICIs hold promise for advanced NSCLC in older adults, but tailored approaches and greater elderly inclusion in trials are needed to optimize outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Mohammed VI University Hospital, Marrakech 40000, Morocco.
- Laboratory of Biosciences and Health, Faculty of Medicine and Pharmacy, Cadi Ayyad University, Marrakech 40000, Morocco.
- Medical Oncology Department, Avicenna Military Hospital, Marrakech 40000, Morocco.
ORCID-Profile: Anass Baladi, Ismail Essaadi, Mohammed El Fadli
Zitieren
APA
Baladi, A., Tafenzi, H. A., Zouiten, O., Afani, L., Essaadi, I., El Fadli, M., & Belbaraka, R. (2025). Immunotherapy for Elderly Patients with Advanced Non-Small Cell Lung Cancer: Challenges and Perspectives. International Journal of Molecular Sciences, 26(5), 2120. https://doi.org/10.3390/ijms26052120
Vancouver
Baladi A, Tafenzi HA, Zouiten O, Afani L, Essaadi I, El Fadli M, et al. Immunotherapy for Elderly Patients with Advanced Non-Small Cell Lung Cancer: Challenges and Perspectives. International Journal of Molecular Sciences. 2025;26(5):2120. doi:10.3390/ijms26052120
BibTeX
@article{Baladi2025,
author = {Baladi, Anass and Tafenzi, Hassan Abdelilah and Zouiten, Othmane and Afani, Leila and Essaadi, Ismail and El Fadli, Mohammed and Belbaraka, Rhizlane},
title = {Immunotherapy for Elderly Patients with Advanced Non-Small Cell Lung Cancer: Challenges and Perspectives},
journal = {International Journal of Molecular Sciences},
year = {2025},
volume = {26},
number = {5},
pages = {2120},
doi = {10.3390/ijms26052120}
}
EUVIMED